Vimarsana
Biggest News Aggregation in the World

Page 11 - Timothy Springer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Timothy Springer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Timothy Springer Today - Breaking & Trending Today

Coronavirus pandemic creates 9 new Big Pharma billionaires - Vimarsana News

Coronavirus pandemic creates 9 new Big Pharma billionaires

The coronavirus (COVID-19) pandemic has created nine new billionaires from the pharmaceutical industry. Campaigners from the People's Vaccine Alliance, whose members include Global Justice [...]

COVID pandemic spawns vaccine billionaires amid global mass death - Vimarsana News

COVID pandemic spawns vaccine billionaires amid global mass death

The profits reaped off vaccine production have produced nine new billionaires, amid record deaths and a denial of vaccinations for the vast majority of the world’s population.

Source: wsws.org
Severe Disease Increases Necessity For A Patient-Centric Approach - Vimarsana News

Severe Disease Increases Necessity For A Patient-Centric Approach

Spinal muscular atrophy (SMA) is a disease caused by a genetic deficiency in a gene known as SMN1, which leads to patients being unable to perform...

60 Biggest Movers From Yesterday - Vimarsana News

60 Biggest Movers From Yesterday

Gainers Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday. Flywire Corporation (NASDAQ: FLYW) gained 46.3% to settle at $35.10 after the company priced its IPO at $24 per share. Build-A-Bear Workshop, Inc. (NYSE: BBW) rose 39.3% to close at $14.07 after the company reported better-than-expected Q1 results and raised FY21 EBITDA guidance. Owens & Minor, Inc. (NYSE: OMI) climbed 36.2% to close at $44.12 on Wednesday....

Source: msn.com
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABBV) - The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs - Vimarsana News

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABBV) - The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs

Pfizer, Inc. (NYSE: PFE) and Myovant Sciences (NYSE: MYOV) announced FDA approval for once-daily Myfembree, relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months. The companies said they will jointly commercialize Myfembree in the U.S. Myfembree is expected to be available in June. Pfizer shares edged down 0.15% to $38.86 in after-hours trading and Myovant receded 0.34% to $23.60. Zosano Announces Publication Of Positive Results Fro...